Many approaches have been developed to improve the physical/chemical properties, potency and selectivity of antibody-drug conjugates (ADCs). Trastuzumab (Tz), a monoclonal antibody targeting HER2, was approved by the FDA in […]
Many approaches have been developed to improve the physical/chemical properties, potency and selectivity of antibody-drug conjugates (ADCs). Trastuzumab (Tz), a monoclonal antibody targeting HER2, was approved by the FDA in […]